

Ahern S, Cervin A. Inflammation and endotyping in chronic rhinosinusitis – a paradigm shift. *Medicina*. 2019;55(4).pii:E95.

Bachert C, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet*. 2019;394(10209):1638-1650.

Bachert C, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. *J Allergy Clin Immunol*. 2017;140(4):1024-1031.e14.

Benjamin MR, et al. Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting. *J Allergy Clin Immunol Pract*. 2019;7(3):1010-1016.

Bhattacharyya N, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. *Laryngoscope*. 2019;129(9):1969-1975.

Cain RB, Lal D. Update on the management of chronic rhinosinusitis. *Infect Drug Resist*. 2013;6:1-14.

ClinicalTrials.gov. A clinical trial of omalizumab in participants with chronic rhinosinusitis with nasal polyps (POLYP 1). <https://clinicaltrials.gov/ct2/show/NCT03280550>. Accessed November 27, 2019.

ClinicalTrials.gov. A clinical trial of omalizumab in participants with chronic rhinosinusitis with nasal polyps (POLYP 2). <https://clinicaltrials.gov/ct2/show/NCT03280537>. Accessed November 27, 2019.

Dupilumab [Package insert]. Tarrytown, NY: Regeneron/Sanofi Genzyme; 2019.

Fokkens WJ, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. [published online May 15, 2019]. *Allergy*. doi:10.1111/all.13875.

Han JK. Subclassification of chronic rhinosinusitis. *Laryngoscope*. 2013;123:S15-27.

Hopkins C. Chronic rhinosinusitis with nasal polyps. *N Engl J Med*. 2019;381:55-63.

Press release. Omalizumab significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies. June 3, 2019. <https://www.novartis.com/news/media-releases/xolair-omalizumab-significantly-reduced-nasal-polyps-and-congestion-symptoms-adults-chronic-rhinosinusitis-nasal-polyps-two-phase-iii-studies>. Accessed November 29, 2019.

Rosati MG and Peters AT. Relationships among allergic rhinitis, asthma, and chronic rhinosinusitis. *Am J Rhinol Allergy*. 2016; 30(1):44-47.

Rosenfield RM, et al. Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg*. 2015;152(2 Suppl):S1-S39.

Smith KA, et al. Cost of adult chronic rhinosinusitis: A systematic review. *Laryngoscope*. 2015;125(7):1547-1556.